187 related articles for article (PubMed ID: 11168547)
1. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies.
Porcella A; Maxia C; Gessa GL; Pani L
Eur J Neurosci; 2001 Jan; 13(2):409-12. PubMed ID: 11168547
[TBL] [Abstract][Full Text] [Related]
2. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys.
Chien FY; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2003 Jan; 121(1):87-90. PubMed ID: 12523891
[TBL] [Abstract][Full Text] [Related]
3. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2.
Song ZH; Slowey CA
J Pharmacol Exp Ther; 2000 Jan; 292(1):136-9. PubMed ID: 10604940
[TBL] [Abstract][Full Text] [Related]
4. [Cannabinoid applications in glaucoma].
Pinar-Sueiro S; Rodríguez-Puertas R; Vecino E
Arch Soc Esp Oftalmol; 2011 Jan; 86(1):16-23. PubMed ID: 21414525
[TBL] [Abstract][Full Text] [Related]
5. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure.
Szczesniak AM; Maor Y; Robertson H; Hung O; Kelly ME
J Ocul Pharmacol Ther; 2011 Oct; 27(5):427-35. PubMed ID: 21770780
[TBL] [Abstract][Full Text] [Related]
6. Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action.
Oltmanns MH; Samudre SS; Castillo IG; Hosseini A; Lichtman AH; Allen RC; Lattanzio FA; Williams PB
J Ocul Pharmacol Ther; 2008 Feb; 24(1):104-15. PubMed ID: 18201139
[TBL] [Abstract][Full Text] [Related]
7. Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists.
Hudson BD; Beazley M; Szczesniak AM; Straiker A; Kelly ME
J Pharmacol Exp Ther; 2011 Dec; 339(3):757-67. PubMed ID: 21885619
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues.
Stamer WD; Golightly SF; Hosohata Y; Ryan EP; Porter AC; Varga E; Noecker RJ; Felder CC; Yamamura HI
Eur J Pharmacol; 2001 Nov; 431(3):277-86. PubMed ID: 11730719
[TBL] [Abstract][Full Text] [Related]
9. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
Rawls SM; Cabassa J; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Jun; 301(3):963-8. PubMed ID: 12023525
[TBL] [Abstract][Full Text] [Related]
10. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation.
Niederhoffer N; Szabo B
Br J Pharmacol; 1999 Jan; 126(2):457-66. PubMed ID: 10077239
[TBL] [Abstract][Full Text] [Related]
11. Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits.
Hodges LC; Reggio PH; Green K
Ophthalmic Res; 1997; 29(1):1-5. PubMed ID: 9112260
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids cause central sympathoexcitation and bradycardia in rabbits.
Niederhoffer N; Szabo B
J Pharmacol Exp Ther; 2000 Aug; 294(2):707-13. PubMed ID: 10900251
[TBL] [Abstract][Full Text] [Related]
13. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
14. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Fattore L; Cossu G; Martellotta CM; Fratta W
Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
[TBL] [Abstract][Full Text] [Related]
15. Topical cannabinoid antinociception: synergy with spinal sites.
Dogrul A; Gul H; Akar A; Yildiz O; Bilgin F; Guzeldemir E
Pain; 2003 Sep; 105(1-2):11-6. PubMed ID: 14499415
[TBL] [Abstract][Full Text] [Related]
16. Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat.
Verrico CD; Jentsch JD; Dazzi L; Roth RH
Synapse; 2003 Jun; 48(4):178-83. PubMed ID: 12687636
[TBL] [Abstract][Full Text] [Related]
17. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human.
Martin RS; Luong LA; Welsh NJ; Eglen RM; Martin GR; MacLennan SJ
Br J Pharmacol; 2000 Apr; 129(8):1707-15. PubMed ID: 10780977
[TBL] [Abstract][Full Text] [Related]
18. Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex.
Steffens M; Szabo B; Klar M; Rominger A; Zentner J; Feuerstein TJ
Neuroscience; 2003; 120(2):455-65. PubMed ID: 12890515
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.
Breivogel CS; Griffin G; Di Marzo V; Martin BR
Mol Pharmacol; 2001 Jul; 60(1):155-63. PubMed ID: 11408610
[TBL] [Abstract][Full Text] [Related]
20. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.
Sánchez AJ; González-Pérez P; Galve-Roperh I; García-Merino A
Biochem Pharmacol; 2006 Dec; 72(12):1697-706. PubMed ID: 17007821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
